The Life Sciences team advised Myrobalan Therapeutics in connection with its $400,000 grant from the ALS Association to support the advancement of its colony-stimulating factor-1 receptor (CSF1R) inhibitor for the treatment of amyotrophic lateral sclerosis (ALS). The grant has been made through the ALS Association's Lawrence and Isabel Barnett Drug Development Program, supplementing the previously announced $24 million in Series A funding in January 2024.
Myro is developing a CSF1R inhibitor to target neuro-inflammation and demyelination with the goal to achieve a more profound therapeutic benefit in a broad patient population. Unlike other CSF1R candidates, Myro's CSF1R inhibitor program was specifically designed for application in central nervous system (CNS) diseases with compelling advantages across several preclinical measures, including potency, selectivity, and CNS distribution. Myro is currently conducting IND-enabling studies and developing a clinical biomarker strategy in preparation for its first-in-human clinical trial expected to begin in 2025. Besides ALS, Myro plans to develop its CSF1R inhibitor in additional neurodegenerative indications such as Multiple Sclerosis and Alzheimer's Disease.
Myrobalan Therapeutics is a preclinical stage biotechnology company headquartered in Medford, Massachusetts, with a focus on developing oral neurorestorative therapies aimed at reversing key pathologies underlying brain dysfunctions and CNS conditions.
The Goodwin team was led by Cui Can and included Xiaowei Wu.
For additional details on the grant, please read the press release.